Predictable Clinical Benefits without Evidence of Synergy in Trials of Combination Therapies with Immune-Checkpoint Inhibitors

Overview of attention for article published in Clinical Cancer Research, January 2022

Altmetric Badge

About this Attention Score

In the top 5% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (98th percentile)
High Attention Score compared to outputs of the same age and source (94th percentile)

Mentioned by

news: 9 news outlets
blogs: 2 blogs

twitter: 121 tweeters
facebook: 2 Facebook pages

Citations

dimensions_citation: 6 Dimensions

Readers on

mendeley: 57 Mendeley

Summary News Blogs Twitter Facebook Dimensions citations

So far, Altmetric has seen 136 tweets from 121 users, with an upper bound of 228,723 followers.

@NCICancerBio A3: By performing an analysis of clinical data, researchers @harvardmed #NCICSBC found that combinations of #immunotherapy improve outcomes by independent drug action. https://t.co/L71MZncVuO #CIMChat22

28 Jun 2022

Reply Retweet Favourite

RT @NCIsysbio: By analyzing #clinicaltrial data in a recent @CCR_AACR study, they found that combinations of #immunecheckpointinhibitors ma…

16 Jun 2022

Reply Retweet Favourite

By analyzing #clinicaltrial data in a recent @CCR_AACR study, they found that combinations of #immunecheckpointinhibitors may improve clinical outcomes by independent drug action rather than synergistic or additive effects. https://t.co/9FJJhwqKAz #CIM22

16 Jun 2022

Reply Retweet Favourite

"Based on retrospective analysis of 13 combination #immunotherapy phase III trials in 8 types of cancer, we conclude that there is no clinical evidence of synergistic or additive interaction among ICIs or ICIs & other drugs" #ICI #CheckpointInhibitors

10 Jun 2022

Reply Retweet Favourite

This page shows the most recent tweets that mention this research output.

Click here to find out how to access more activity, including 132 additional tweets.